Molecular features, biological behaviors and clinical implications of m(5)C RNA methylation modification regulators in gastrointestinal cancers

胃肠道癌症中m(5)C RNA甲基化修饰调控因子的分子特征、生物学行为和临床意义

阅读:2

Abstract

Epitranscriptome studies have shown that critical RNA modifications drive tumorigenicity; however, the role of 5-methylcytosine (m(5)C) RNA methylation remains poorly understood. We extracted 17 m(5)C regulators and clustered distinct m(5)C modification patterns by consensus clustering analysis. Gene set variation and single-sample gene set enrichment analysis were applied to quantify functional analysis and immune infiltration. The least absolute shrinkage and selection operator was employed to develop a prognostic risk score. Kaplan-Meier with log-rank test was used for survival analysis. Differential expression analysis was performed with the "limma" R package. Wilcoxon signed ranked test or Kruskal-Wallis test was used to compare groups. We observed that m(5)C RNA methylation was commonly upregulated in gastrointestinal cancer and related to prognosis. Clusters were identified for m(5)C patterns, with distinct immune infiltrations and functional pathways. The risk scores of m(5)C regulators were independent risk factors. Differentially expressed mRNAs (DEmRNAs) in m(5)C clusters were involved in cancer-related pathways. The methylation-based m(5)Cscore showed a significant effect on the prognosis. Patients with a lower m(5)Cscore exhibited more therapeutic efficiency on anti-CTLA4 therapy in liver cancer, while the combination of anti-CTLA4 therapy and pd1 was more efficient for patients with a lower m(5)Cscore in pancreatic cancer. We uncovered dysregulations of m(5)C-related regulators in gastrointestinal cancer and their associations with overall survival. Some immune cells were differently infiltrated in distinct m(5)C modification patterns, indicating their potential impacts on gastrointestinal cancer cell-immune. Moreover, an m(5)Cscore, derived from DEmRNAs in specific clusters, can serve as a classifier for immunotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。